DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification

Nov.26.2024

DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification

The Philippine Department of Trade and Industry (DTI) has lifted the trade ban on AEROGIN and RELX, while products from brands like FLARE, NIXX, and VAPENGIN still require Philippine Standards (PS) certification before they can be sold.

The Department of Trade and Industry (DTI) has officially lifted the suspension on the sale of vape products produced by AEROGIN and RELX.

At the same time, the DTI has removed the Preliminary Order/Preventive Measure Order against FLARE, NIXX, and VAPENGIN products. However, the sale of these products will remain prohibited until they secure the necessary Philippine Standard (PS) certification.

DTI emphasizes its commitment to ensuring the safety and quality of vape products in the Philippine market through strict enforcement of regulatory standards. Under Republic Act No. 11900 (RA11900), also known as the "Vaporized Nicotine and Non-Nicotine Products Regulation Act," and related regulations, the Office for the Special Mandate on Vaporized Nicotine and Non-Nicotine Products (OSMV) has the authority to take immediate action, including the recall, restriction, or confiscation of non-compliant vape products, devices, or novel tobacco products, following due process.

References:

[1] DTI lifts suspension of vape brands

Also Read:

[1] DTI suspends sales of 11 e-cigarette brands in the Philippines

[2] DTI Initiates Legal Action Against Four E-Cigarette Brands Including RELX, Flare

[3] DTI Suspends Sales of 5 E-cigarette Brands in Philippines, Including LOST MARY, Chillax, SHFTDr.Freeze, Aerogin, Don Bars, Black Elite

[4] Philippine Customs Seizes $33.8k Worth of E-Cigarettes in Warehouses

#Legislation #Asia #Open system e-cigarettes #Philippines

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen

2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen

2Firsts held a UK vape duty stamp compliance exchange in Shenzhen on May 14, bringing together representatives from nearly 20 companies. The session addressed Vaping Products Duty, duty stamp applications, UK agency qualifications and warehousing, while introducing 2Firsts Compliance Solutions’ UK service.

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.

Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials

Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials

CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises

On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.

Apr.23 by 2FIRSTS.ai

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.

BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention

BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention

British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.

Related Topics

News Regulation

Related Read

2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen

2Firsts Hosts UK Vape Duty Stamp Compliance Exchange in Shenzhen

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications

Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials

Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises

PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo

BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention

BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention